In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $1.26.
According to TipRanks, Benjamin is an analyst with an average return of -8.0% and a 34.87% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Incyte, and Iovance Biotherapeutics.
Spectrum Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.67, which is a 429.37% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
SPPI market cap is currently $243.7M and has a P/E ratio of -1.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. The company was founded in December 1987 and is headquartered in Henderson, NV.
Read More on SPPI:
- Cowen & Co. Reaffirms Their Buy Rating on L3Harris Technologies (LHX)
- Vulcan Energy Resources (ASX:VUL) shares soar on key project update
- Australian Stock Market Today – Tuesday September 13: What You Need to Know
- Why GameStop Stock (NYSE:GME) Remains a Newbie Investment
- Twitter Stock: 5-Star Analyst Weighs in Ahead of Big Day
